Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 25 min ago
Peer-reviewedCC BY-NC 4.0Therapeutic Advances in Hematology

Impact of luspatercept in beta-thalassemia major with alloimmunization: A case report

  • Fariha Fairouz1
  • Supat Chamnanchanunt1,2
  • Vipa Thanachartwet1
  • Varunee Desakorn1
  • Suthat Fucharoen3,4
4 affiliations
  1. 1Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
  2. 2Division of Hematology, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand
  3. 3Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand
  4. 4Samitivej Srinakarin Hospital, Bangkok, Thailand
Read full textPDFDOICite

Abstract

Patients with Beta (β)-thalassemia require regular blood transfusions. The presence of red blood cell (RBC) alloantibodies can complicate transfusion treatment. This can lead to delays in obtaining compatible blood, and in some case temporarily rendering blood transfusion impossible. We present a case demonstrating the successful adjunctive management of a patient with transfusion-dependent β-thalassemia complicated by RBC alloimmunization using a novel therapeutic agent. A 32-year-old Thai female with homozygous β-thalassemia was admitted to the Hospital of Tropical Diseases, Bangkok, with symptoms of anemia. Cross-matching studies revealed the presence of alloantibodies at admission. Treatment with luspatercept, a novel erythroid maturation agent, resulted in an increase in hemoglobin levels and an extension of the transfusion interval. The patient received four doses of luspatercept while awaiting antigen-compatible RBC units. Although luspatercept had no direct effect on RBC alloimmunization or existing alloantibodies, its ability to reduce transfusion requirements may decrease the need for subsequent RBC transfusions, and thereby reduce further antigen exposure. This may be particularly beneficial in patients with complex alloantibody profiles. This case highlights the potential role of luspatercept as adjunctive supportive therapy to delay transfusions requirements in patients with transfusion-dependent β-thalassemia complicated by RBC alloimmunization.

Related

  1. Luspatercept in myelodysplastic syndrome with ring sideroblasts: a case report of intrapulmonary vascular dilatation syndrome causing protracted inexplicable hypoxia
    Ayesha Warsi, Marie E. Faughnan, Rena Buckstein
    HaematologicaPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMC
  2. Comments on “surface-based brain age index reflects hematological impacts on cognitive development in children with beta-thalassemia major”
    iSciencePeer-reviewedCC BY 4.0Human geneticsCell PressCrossref
  3. Assessment of Body Mass Index (BMI) in Patients With Beta Thalassemia Major (β-TM): A Hospital-Based Study
    Divya Gupta, Onkar Awadhiya, Ashok Kumar +1
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Secondary (anamnestic) anti D alloimmunization following transfusion of a DEL phenotype rhesus D negative unit: A case report highlighting the need for DEL screening in India.
    Priyasha Prajapat, Rasika Dhawan Setia, Mitu Dogra
    Asian journal of transfusion sciencePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCPMC
  5. SF3B1-mutated MDS coexisting with β-thalassemia trait : A case report and literature review focused on diagnostic distinction from acquired β-thalassemia
    Zenghui Fang, Lu Chen, Menghe Zhao +1
    MedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{fairouz2026impact,
  title = {{Impact of luspatercept in beta-thalassemia major with alloimmunization: A case report}},
  author = {Fariha Fairouz and Supat Chamnanchanunt and Vipa Thanachartwet and Varunee Desakorn and Suthat Fucharoen},
  journal = {Therapeutic Advances in Hematology},
  year = {2026},
  month = sep,
  doi = {10.1177/20406207261491921},
  url = {https://doi.org/10.1177/20406207261491921},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Impact of luspatercept in beta-thalassemia major with alloimmunization: A case report
AU  - Fariha Fairouz
AU  - Supat Chamnanchanunt
AU  - Vipa Thanachartwet
AU  - Varunee Desakorn
AU  - Suthat Fucharoen
PY  - 2026
DA  - 2026/09/18
JO  - Therapeutic Advances in Hematology
DO  - 10.1177/20406207261491921
UR  - https://doi.org/10.1177/20406207261491921
AB  - Patients with Beta (β)-thalassemia require regular blood transfusions. The presence of red blood cell (RBC) alloantibodies can complicate transfusion treatment. This can lead to delays in obtaining compatible blood, and in some case temporarily rendering blood transfusion impossible. We present a case demonstrating the successful adjunctive management of a patient with transfusion-dependent β-thalassemia complicated by RBC alloimmunization using a novel therapeutic agent. A 32-year-old Thai female with homozygous β-thalassemia was admitted to the Hospital of Tropical Diseases, Bangkok, with symptoms of anemia. Cross-matching studies revealed the presence of alloantibodies at admission. Treatment with luspatercept, a novel erythroid maturation agent, resulted in an increase in hemoglobin levels and an extension of the transfusion interval. The patient received four doses of luspatercept while awaiting antigen-compatible RBC units. Although luspatercept had no direct effect on RBC alloimmunization or existing alloantibodies, its ability to reduce transfusion requirements may decrease the need for subsequent RBC transfusions, and thereby reduce further antigen exposure. This may be particularly beneficial in patients with complex alloantibody profiles. This case highlights the potential role of luspatercept as adjunctive supportive therapy to delay transfusions requirements in patients with transfusion-dependent β-thalassemia complicated by RBC alloimmunization.
SN  - 2040-6207
SN  - 2040-6215
ER  -